Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 36Unknown 9Terminated 5Withdrawn 2Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 6Leukemia, Biphenotypic, Acute 2Sarcoma, Myeloid 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia, Monocytic, Acute 1Leukemia 1

Interventions

venetoclax 21Cyclophosphamide 14Cytarabine 12Azacitidine 8fludarabine 7Dexamethasone 5Daunorubicin 5ruxolitinib 4revumenib 4Trimethoprim, Sulfamethoxazole Drug Combination 4quizartinib 3pirtobrutinib 3gamma-Globulins 3fludarabine phosphate 3blinatumomab 3Tacrolimus 3Rituximab 3Palliative Care 3Inotuzumab Ozogamicin 3Granulocyte Colony-Stimulating Factor 3Decitabine 3Ciprofloxacin 3Blood Specimen Collection 3zanubrutinib 2ponatinib 2pembrolizumab 2ibrutinib 2aldesleukin 2acalabrutinib 2Watchful Waiting 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Leukemia × Mitoxantrone × Clear all
NCT06429449 2026-01-15

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

University of Colorado, Denver

Phase 1 Recruiting
30 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Monocytic, Acute, Leukemia, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡